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HPT development is associated with the progressing chronic transplant nephropathy that eventually develops in all recipients, and occurs by the same mechanisms as the secondary HPT in CKD. In such cases, the recipients could have had a mild or moderately severe HPT course in the pre-transplant period, then experienced an improvement after successful kidney transplantation, and they could even avoid secondary HPT. With a prolonged reduction of the renal graft function without its correction, the HPT progresses to a severe course with the development of PTG nodular hyperplasia, i.e. the tertiary HPT [2] .
With a reduced kidney graft function immediately after the transplant surgery, the secondary HPT existing before kidney transplantation does not completely regress, but continues to persist. As in the above case, an inadequate correction entails the risk of further progression to tertiary HPT with PTG nodular hyperplasia development (2, 3).
Post-transplant (tertiary) HPT can be diagnosed as early as in the first year after kidney transplantation, regardless of the kidney graft function. In this case, the HPT existence can be explained by a varied autonomy of PTG diffused-nodular/nodular hyperplasia that was formed before the kidney transplantation, i.e. by the severe HPT resulted from an inadequate treatment [2, 3] The identified risk factors for HPT persisting after kidney transplantation include: the high blood levels of PTH, calcium, phosphorus and(or) alkaline phosphatase, a long-term dialysis therapy, and the pretransplant therapy with cinacalcet reflecting a severe pre-transplant course of HPT, a vitamin D [25(OH)D] deficiency, and a suboptimal function of the transplanted kidney [3, [5] [6] [7] . The risk group of post-transplant HPT development also includes the recipients who previously underwent a 5 subtotal or incomplete parathyroidectomy (PTE). There was interesting information about the possible role of the recipient high body mass index in the post-transplant HPT development that is explained by the effect of leptin stimulating the PTH secretion [8] .
The morphological substrate of post-transplant HPT may also be diverse corresponding to the complexity of genesis. More often it is represented by asymmetric hyperplasia of all four, (or less frequently of one or two) PTGs, most likely due to an uneven gland involution after successful kidney transplantation. Single or double adenoma of PTG is also be found in the kidney transplant recipients and can be of a dual origin: sporadic primary HPT or the adenomatous transformation of the hyperplasia-affected gland in secondary HPT [2] .
Epidemiology
The information on the prevalence of post-transplant HPT is scanty and reported in foreign publications. Noteworthy are the significant variations in the HPT incidence rates between renal transplant recipients. This is mainly due to the fact that, in contrast to dialysis patients, the targeted PTH blood levels in transplant patients have not been clearly defined. The Russian national and some foreign clinical recommendations state the same values as those indicated for the corresponding stage of CKD, however, the studies demonstrated a higher blood level of PTH in the kidney transplant recipients than that in CKD patients with similar GFR [3, 9, 10] .
Therefore, analyzing the prevalence of post-transplant HPT, some authors diagnosed it at PTH level 2 times higher than the upper limit of reference values (i.e. exceeding 130 pg/mL), and others did at the level of 2.5 times higher [5, 11] . It is even more difficult to evaluate the incidence of HPT in 6 kidney transplantation centers of Russia, since the monitoring of PTH and other mineral and bone metabolism markers is not a routine in every recipient. Our study showed that only some recipients, including those in the group with an optimal kidney function and the post-transplant period duration of 1 to 5 years, had the plasma PTH concentrations within the target ranges as indicated in the national clinical recommendations [4, 9] . Data from the literature indicate different HPT incidence rates at different times of the post-transplant period: it is the highest in the first posttransplant year and significantly lower in subsequent years. Thus, specifically, a recently completed American prospective multicenter observational study involving 246 recipients demonstrated that the PTH levels observed in the first postoperative year were beyond the reference values in more than 80% of recipients, and over 130 pg/mL in 40% [6] . The similar data were also reported in another small study where 50%, and 41% among 143 kidney transplant recipients, had HPT (the PTH level over 130 pg/mL) at 3 months, and at 1 year after transplantation, respectively [5] .
Meanwhile, a large retrospective observational study showed that in the first year after successful kidney transplantation, only 18% of recipients (108 of 607) had elevated PTH levels; and in 8% (n=47), the elevated PTH levels were coincided with hypercalcemia [10] . The analysis of the natural course of PTG function and the calcium-phosphorus metabolism for several years also yielded a considerable scatter of values. Thus, P. Evenepoel et al. [11] who followed-up 861 renal transplant recipients for 4 years indicated only 17% of those who had either an elevated PTH level (2.5 times higher of upper limit of normal) or underwent a PTE. E.R. Perrin et al. [5] followedup the patients after kidney transplantation for 5 years and diagnosed HPT in a third of recipients at the end of the study period. 7 Post-transplantation HPT has a significant effect on the survival quality and length of recipients and renal transplants. A correlation was found between the elevated PTH levels (> 140 pg/mL at 2.5-3 months after surgery) and the development of cardiovascular complications, graft loss, and an increased risk of all-cause mortality [10] .
Clinical and laboratory manifestations
Clinical manifestations of pre-and post-transplant (secondary) HPT are of uniform nature, and the post-transplant (tertiary) HPT symptoms are diverse and resemble those of primary HPT, meanwhile, they are associated both with the excessive blood content of PTH, and with persistent hypercalcemia. They include the bone pathology development, the damage to the kidney graft and other organ systems.
Bone pathology is usually represented by a hypermetabolic bone disease, fibrotic osteitis, and osteopenic syndrome. Post-transplant HPT is the leading cause of mineral bone mass loss in the bones of the cortical structure (femoral neck, radial bone) predisposing them to fractures. The correlation of HPT with the susceptibility to bone fractures is known in dialysis patient population, and in primary HPT. Recently, the same relationship has been established for renal transplant recipients. A retrospective study that included 143 patients who underwent kidney transplantation from August 2004 to April 2006 showed that the PTH level over 130 pg/mL persisting for 3 months was an independent risk factor for the occurrence of bone fractures in the post-transplant period, the greatest risk being in the first year after surgery when the incidence of fractures is the highest [5] . 8 Another serious consequence of post-transplant (tertiary) HPT is the damage to the kidney graft and its decreased function which occurrence is closely related to hypercalcemia; the latter initiates the vasoconstriction and leads to hypercalciuria followed by the development of tubulointerstitial lesions, the kidney calcinosis or lithiasis. The kidney transplant calcification (calcium phosphate deposits in the lumen of tubules) was confirmed by the protocol biopsy performed in the first year after surgery. Such patients had significantly higher serum levels of PTH and calcium, and a lower kidney function by the end of the first year [3] .
Hypercalcemia and associated hypercalciuria explain the syndrome of polyuria and polydipsia. Excessive calcium in the urine causes the activation of calcium-sensitive receptors expressed in many sites of the nephron and, primarily, in the distal part of the Henle loop, which leads to an increased intratubular fluid amount and the polyuria development [12, 13] . In addition, hypercalcemia contributes to the kidney resistance to vasopressin, i.e. the development of a nephrogenic diabetes insipidus.
The most important systemic effect of post-transplant HPT is the vascular calcification that has an unfavorable prognosis for the cardiovascular system and is associated with a high risk of coronary heart disease and more frequent indications to coronary artery bypass grafting, a Hypophosphatemia is a consequence of phosphaturia, as a rule, in the longterm post-transplant period, the same as and in the early postoperative period, but not due to the phosphaturic effect of FGF23 which level is lower than in patients with CKD at the corresponding stage, but due to the phosphaturic action of PTH, which level, on the contrary, is higher than at the same stage of CKD. The above has been confirmed by the direct relationship between the fractional urinary excretion of phosphorus and the blood level of PTH [18] . Hypercalcemia in combination with hypophosphatemia is associated with a decreased renal transplant function in the first postoperative year [19] .
Diagnosis
The strategy to diagnose HPT in renal transplant recipients includes primarily the monitoring of serum concentrations of PTH, phosphorus, and calcium, the alkaline phosphatase activity (bone-specific and(or) total) in blood, the kidney transplant function, and, advisably, the vitamin D There are two aspects to be discussed separately: the first one is the reason to determine the ionized calcium level, since measuring only the total calcium concentration in blood strongly underestimates the hypercalcemia diagnosis; and the second aspect is the necessity and periodicity of studying the serum magnesium concentration, given the high incidence of hypomagnesemia in the post-transplant period [3, 21] . as an osteoanabolic agent, to some extent resists to the proapoptotic effect of glucocorticosteroids on osteoblasts [38] . Along with this, the question on the timing of expectant management for severe HPT in kidney transplant 16 recipients does not have an unambiguous answer, it requires scrupulous "weighing all the pros and cons".
As for the extent of surgical intervention, PTE can be subtotal or total; the latter, respectively, being performed either with the autotransplantation of a PTG fragment subcutaneously/into the muscle, or without it. The choice of surgery remains to the surgeon's discretion and is determined in each case individually. So, T.M. Hsieh et al. [39] studied 14 (of 488) renal transplant recipients who underwent surgery for tertiary HPT: either a total PTE (n=7), or a subtotal PTE (n=7). The authors found no differences between the two groups in surgery duration, in-hospital length of stay, laboratory parameters except for blood levels of calcium and phosphorus. The patients who underwent the total PTE had a lower serum calcium concentration and a higher serum phosphorus concentration than the patients who underwent the subtotal PTE. Based on that, the authors concluded that subtotal PTE is preferable, since it reduces the risk of postoperative hypocalcemia. Probably, subtotal PTE is preferable also from the point of keeping the protective effect of PTH on bone tissue [40] .
Another study presented the results of a total PTE without PTG fragment autotransplantation in 26 kidney recipients who postoperatively received 1-α-kalcidiol; all patients were alive after 5 years, 20 patients survived over 9 years. The serum calcium concentrations and blood PTH levels remained normal both after 5 years, and after 9 years; on that basis, the authors concluded that the total PTE without PTG fragment autotransplantation prevents both the persistence and the recurrence of HPT [41] .
Previously, the development of recurrent HPT after PTE in recipients with a satisfactory renal transplant function was believed unlikely. However, 17 K. Schlosser et al. [42] identified 24 such patients (of 69) who underwent PTE in the post-transplant period; in 8 of them, the HPT was related to the PTG autograft. After the latter was removed and examined, the alterations consistent to nodular hyperplasia and the adenomatous transformation of the PTG were found, most likely, originally taking place in the transplanted fragment of the gland, despite a careful preliminary selection of the fragments. Therefore, in the authors' opinion, the total PTE without PTG fragment autotransplantation seemed to be the best surgical strategy for tertiary HPT treatment. In order to avoid the persistence and recurrence of tertiary HPT after the PTE, some authors consider it reasonable to perform the intraoperative monitoring of PTH, the same way as in primary HPT [43] .
However, in contrast to primary HPT, in some patients with tertiary HPT, a more than 50% PTH decrease is recorded at 25 minutes rather than at 10 minutes after the adequate resection of the PTG.
The PTE outcomes in renal transplant recipients are generally optimistic. L.K. Dewberry et al. [33] evaluated the surgery outcomes in the period 1994-2013 and showed that hypercalcemia resolved in 97% of patients, the transient hypocalcemia was identified in 27%. The blood level of PTH after surgery decreased from 745 (285-1594) pg/mL to 97 pg/mL; in the long-term period, the median PTH was below 259 pg/mL in 78% of patients, and was 535 pg/mL in 22%. No deaths were recorded in the early postoperative period. A year after PTE, the GFR was 53 ± 28 ml/min vs. the preoperative GFR equal to 58 ± 28 ml/min. There is another aspect of the surgical treatment for HPT in renal transplant recipients that is under discussion: whether PTE should be performed in patients awaiting for kidney transplantation who have severe HPT responding to a drug therapy. It is suggested that PTE should be performed in the pre-transplant period in order to prevent the tertiary HPT occurrence and to minimize the risk of renal graft function impairment during the surgical treatment; and here the subtotal PTG removal is the optimal technique. This will avoid the need for PTE after kidney transplantation and at the same time retain the PTG function, preventing the development of adynamic bone disease [39] . One of the studies, a prospective, randomized, controlled trial evaluating the effect of oral paricalcitol (administered on the 3 rd day after the surgery) on the HPT incidence by the end of the first year after kidney transplantation showed a 29% HPT rate in the paricalcitol-treated group and 63% in the control group. Significant differences between the groups in blood levels of PTH were recorded at one month after the initiation of paricalcitol use, remained the same trend throughout the year; and at the end of the study period, the blood PTH levels made 42 pg/mL in the paricalcitol group versus 85 pg/mL in the control group (p = 0.0004). Similar dynamic changes were observed in daily calciuria, but it did not exceed 250 mg/day.
The authors did not find differences between the groups in bone-specific alkaline phosphatase activity, serum calcium, phosphorus and vitamin D, in densitometry parameters, and the renal transplant function, although in latter case, the incidence of moderate to severe interstitial fibrosis, and the inflammation signs were more frequently recorded in the control group. studies: an observational study, a retrospective multicenter study, and a single-center prospective randomized controlled cross-over study [51] [52] [53] .
Cinacalcet, a drug from the class of calcimimetics, has been used for a temporary correction of hypercalcemia in tertiary HPT. Cinacalcet has not
been approved yet for HPT treatment in patients after kidney transplantation, in the cinacalcet group, and in 3.5% in the placebo group. The secondary endpoints: the changes in bone mineral density (BMD) at the femoral neck and in bone turnover markers were similar in two groups, and the dynamics changes of phosphatemia were positive in the cinacalcet group. The plasma PTH level in the study group decreased by 128 ± 34 pg/mL, the calculated GFR remained stable in both groups. Based on the data obtained, the authors concluded that cinacalcet provides an effective correction of hypercalcemia, hypophosphatemia, and PTG hyperfucntion in the patients after kidney transplantation [59] . 25 Some researchers express their concern about ambiguous data on the effect of cinacalcet cessation on the urinary calcium excretion, the graft function, and also the PTG function [3, 20, 47] .
Meanwhile, recent reports indicate that cinacalcet increases calciuria only temporary, during the first 8 hours after intake; the decrease in kidney function is relatively minor and temporary, being reversal after the drug withdrawal, and this decrease is most likely related to renal hemodynamic shifts, rather than structural disorders. The drug displays no adverse interactions with standard immunosuppressive therapies [7, 58, 59 ].
However, the question of the cinacalcet administration and therapy duration remains open.
Conclusion
HPT is associated with mineral bone disorders after kidney transplantation and has a significant effect on the long-term recipient and transplant survival rates. The authors state there is no conflict of interests to declare
